Abstract: A multi-beam charged particle microscope system, having a mirror mode of operation, can be operated to record a stack of images in a mirror imaging mode. The stack of images comprises at least two images of two different settings of at least on multi-aperture element, for example a focus stack, which allows the multi-beam charged particle microscope system to be inspected and recalibrated thoroughly. Related methods computer program products are disclosed.

Abstract: The invention relates to a cosmetic spray consisting of a) an oil-in-water emulsion (O/W emulsion) containing sodium stearoyl glutamate and b) a spray applicator system.

Abstract: Cosmetic product of a) a packaging of high-density polyethylene (HDPE), low-density polyethylene (LDPE), polypropylene (PP) or polyethylene terephthalate (PET), and b) a cosmetic preparation containing propylene glycol diester.

Abstract: Cosmetic product of a) a packaging of high-density polyethylene (HDPE), low-density polyethylene (LDPE), polypropylene (PP) or polyethylene terephthalate (PET), and b) a cosmetic preparation containing triolein.

Abstract: Cosmetic product of a) a packaging of high-density polyethylene (HDPE), low-density polyethylene (LDPE), polypropylene (PP) or polyethylene terephthalate (PET), as well as b) a cosmetic preparation containing ethylhexyl oxystearate ester.

Abstract: The present invention relates to novel liquid pharmaceutical compositions comprising proteins, preferably antibodies as defined herein together with one or more surfactants selected from TPGS, PVA, T1107, Px338, Px407, TMN-6, 15-S-15, Chol-PEG, and SL.

Abstract: Cosmetic oil-in-water emulsion (O/W emulsion) containing a) hydroxypropyl starch phosphate and b) one or more perfumes selected from the group of the compounds of the tertiary alcohols, acyclic terpinolenes, and benzopyrones, wherein the preparation is free of carbomers and polyacrylates.

Abstract: Cosmetic product of a) a cosmetic preparation containing hydroxypropyl starch phosphate (INCI: Hydroxypropyl Starch Phosphate) and b) a packaging with a dispensing opening in the form of a hole from which the cosmetic preparation can be dispensed in the form of a flow.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: This invention relates to a pharmaceutical formulation of a bispecific anti-VEGF/ANG2 antibody, and a process for the preparation and uses of the formulation.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: The invention relates to a cosmetic spray consisting of a) an oil-in-water emulsion (O/W emulsion) containing poly glyceryl-10 stearate and b) a spray applicator system.

Abstract: The invention relates to a cosmetic foam made from a) an O/W emulsion containing glycerine and b) mono- and/or polyvalent alcohols with a carbon chain length of less than 12 C-atoms and c) a gas or gas mixture of propane, n-butane and/or isobutane, foaming the emulsion, which emulsion is fre of polyethylene glycol derivatives (PEG derivatives).

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: The invention relates to a cosmetic foam of a) an emulsion containing a combination of sodium cetearyl sulfate and glyceryl monostearate SE and b) a gas or gas mixture of propane, n-butane and/or isobutane, foaming the emulsion, the emulsion being free of polyethylene glycol derivatives (PEG derivatives).

Abstract: Anti-CD40 antibodies are formulated as lyophilizate or liquid formulation. The lyophilizates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilizate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilizate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: Anti-CD40 antibodies are formulated as lyophilisate or liquid formulation. The lyophilisates can be reconstituted to give a solution with a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The lyophilisate can be reconstituted with an aqueous reconstituent to provide an aqueous composition in which the antibody has a concentration of at least 50 mg/ml. The lyophilisate or aqueous pharmaceutical composition may include one or more of a sugar, a buffering agent, a surfactant, and/or a free amino acid.

Abstract: The invention relates to a cosmetic spray which consists of a) an oil-in-water emulsion (O/W emulsion) that contains i) polyglyceryl-3 methylglucose distearate and ii) acrylate/C10-30 alkyl acrylate crosspolymer, and b) a spray applicator system.

Abstract: The invention relates to a cosmetic spray consisting of a) an oil-in-water emulsion (O/W emulsion) containing poly glyceryl-10 stearate and b) a spray applicator system.